Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

Journal of Experimental Medicine

Volumn 184, Issue 2, 1996, Pages 465-472

  Boczkowski, David ^a   Nair, Smita K ^a   Snyder, David ^a   Gilboa, Eli ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNIZATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA TRANSCRIPTION; TUMOR IMMUNITY; TUMOR REJECTION;

EID: 0029839058     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.184.2.465     Document Type: Article

References (35)

1. Steinman, R.M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271-296.
2. Flamand, V., T. Sornasse, K. Thielemans, C. Demanet, M. Bakkus, H. Bazin, F. Tielemans, O. Leo, J. Urgain, and M. Moser. 1994. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24:605-610.
3. Hsu, F.J., C. Benike, F. Fagnoni, T.M. Liles, D. Czerwinski, B. Taidi, E.G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52-58.
4. Paglia, P., C. Chiodoni, M. Rodolfo, and M.P. Colombo. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317-322.
5. Porgador, A., D. Snyder, and E. Gilboa. 1996. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:2918-2926.
6. Porgador, A., and E. Gilboa. 1995. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182: 255-260.
7. Ossevoort, M.A., M.C.W. Feltkamp, K.J.H. van Veen, C.J.M. Melief, and W.M. Kast. 1995. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J. Immunother. 18:86-94.
8. Mayordomo, J.I., T. Zorina, W.J. Storkus, L. Zitvogel, C. Celluzzi, L.D. Falo, C.J. Melief, S.T. Ildstad, W.M. Kast, A.B. Deleo, and M.T. Lotze. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297-1302.
9. Celluzzi, C.M., J.I. Mayordomo, W.J. Storkus, M.T. Lotze, and J.L.D. Falo. 1996. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183:283-287.
10. Finn, O.J. 1993. Tumor-rejection antigens recognized by T lymphocytes. Curr. Opin. Immunol. 5:701-708.
11. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725-729.
12. Anichini, A., R. Mortarini, C. Maccalli, P. Squarcina, K. Fleischhauer, L. Mascheroni, and G. Parmiani. 1996. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J. Immunol. 156:208-217.
13. Johnston, J.V., A.R. Malacko, M.T. Mizuno, P. McGowan, I. Hellstrom, K.E. Hellstrom, H. Marquardt, and L. Chen. 1996. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J. Exp. Med. 183:791-800.
14. Shimizu, J., T. Suda, T. Yoshioka, A. Kosugi, H. Fujiwara, and T. Hamaoka. 1989. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells. J. Immunol. 142:1053-1059.
15. Grabbe, S., S. Bruvers, R.L. Gallo, T.L. Knisely, R. Nazareno, and R.D. Granstein. 1991. Tumor antigen presentation by murine epidermal cells. J. Immunol. 146:3656-3661.
16. Zitvogel, L., J.I. Mayordomo, T. Tjandrawan, A.B. DeLeo, M.R. Clarke, M.T. Lotze, and W.J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87-97.
17. Parmiani, G. 1993. Tumor immunity as auto immunity: tumor antigens include normal self-proteins which stimulate anergic peripheral T cells. Immunol. Today. 14:536-538.
18. Houghton, A.N. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1-4.
19. Martinon, F., S. Krishnan, G. Lenzen, R. Magne, E. Gomard, J.-G. Guillet, J.-P. Levy, and P. Meulien. 1993. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 23:1719-1722.
20. Conry, R.M., A.F. LoBuglio, M. Wright, L. Sumerel, M.J. Pike, F. Johanning, R. Benjamin, D. Lu, and D.T. Curiel. 1995. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 55:1397-1400.
21. Qui, P., P. Ziegelhoffer, J. Sun, and N.S. Yang. 1996. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Ther. 3:262-268.
22. Macatonia, S.E., P.M. Taylor, S.C. Knight, and B.A. Askonas. 1988. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J. Exp. Med. 169:1255-1264.
23. Nair, S., F. Zhou, R. Reddy, L. Huang, and B.T. Rouse. 1992. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J. Exp. Med. 175:609-612.
24. De Bruijn, M.L.H., T.N.M. Schumacher, J.D. Nieland, H.L. Ploegh, W.M. Kast, and C.J.M. Melief. 1991. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. Eur. J. Immunol. 21:2963-2970.
25. Nair, S.K., D. Snyder, and E. Gilboa. 1996. Cells treated with TAP-2 antisense oligonucleotides are potent antigen-presenting cells in vitro and in vivo. J. Immunol. 156:1772-1780.
26. Porgador, A., M. Feldman, and L. Eisenbach. 1989. H-2Kb transfection of B16 melanoma cells results in reduced tumorigenicity and metastatic competence. J. Immunogenet. (Oxf.). 16:291-303.
27. Porgador, A., E. Tzehoval, E. Vadai, M. Feldman, and L. Eisenbach. 1995. Combined vaccination with major histocompatibility class I and interleukin 2 gene-tranduced melanoma cells synergizes the cure of postsurgical established lung metastases. Cancer Res. 55:4941-4949.
28. Ljunggren, H.-G., and K. Karre. 1985. Host resistance directed selectively against H-2-deficient lymphoma variants: analysis of the mechanism. J. Exp. Med. 162:1745-1759.
29. Moore, M.W., F.R. Carbone, and M.J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 54:777-785.
30. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal. Biochem. 162:156-159.
31. Donis-Keller, H. 1979. Site specific enzymatic cleavage of RNA. Nucleic Acids Res. 7:179-192.
32. Walker, C., M. Selby, A. Erickson, D. Cataldo, J.-P. Valensi, and G. van Nest. 1992. Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway. Proc. Natl. Acad. Sci. USA. 89: 7915-7918.
33. Rotzschke, O., K. Falk, S. Stevanovic, G. Jung, P. Walden, and H.G. Rammensee. 1991. Exact prediction of a natural T cell epitope. Eur. J. Immunol. 21:2891-2894.
34. Volgmann, T., A. Klein-Struckmeier, and H. Mohr. 1989. A fluorescence-based assay for quantitation of lymphokine-activated killer cell activity. J. Immunol. Methods. 119:45-51.
35. Carbone, F.R., M.W. Moore, J.M. Sheil, and M.J. Bevan. 1988. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. J. Exp. Med. 167:1767-1779.